Cat. No：GM-87903MAB
Product：Anti-mouse CD25 mIgG2a Antibody(PC-61.5.3)
Cat. No：GM-87903MAB
Product：Anti-mouse CD25 mIgG2a Antibody(PC-61.5.3)
GM-87903MAB-1mg / 1 mg
GM-87903MAB-5mg / 5 mg
GM-87903MAB-25mg / 25 mg
GM-87903MAB-50mg / 50 mg
GM-87903MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CD25
Clone PC-61.5.3
Alternative Names CD25, Il2r, Ly-43, Il2ra
Source/Isotype Monoclonal mouse lgG2a. Kappa
Application /
Description CD25 antibodies selectively target and deplete activated T cells, particularly those expressing CD25, making them potential therapeutic tools for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. They modulate the immune response by reducing the number of activated T cells, thereby alleviating symptoms.In organ transplantation, CD25 antibodies serve as immunosuppressants to prevent the recipient's rejection of the graft, reducing T cell activation and improving transplant success rates. In cancer treatment, CD25 antibodies aim to improve the immune suppression in the tumor microenvironment, restoring anti-tumor immune responses by targeting regulatory T cells. Overall, CD25 antibodies demonstrate broad application potential in the treatment of autoimmune diseases, management of organ transplantation, and cancer immunotherapy, helping to regulate and optimize immune responses.
Formulation phosphate-buffered solution, pH 7.2.
Cat. No：GM-87903MAB
Product：Anti-mouse CD25 mIgG2a Antibody(PC-61.5.3)
GM-87903MAB-1mg / 1 mg
GM-87903MAB-5mg / 5 mg
GM-87903MAB-25mg / 25 mg
GM-87903MAB-50mg / 50 mg
GM-87903MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CD25
Clone PC-61.5.3
Alternative Names CD25, Il2r, Ly-43, Il2ra
Source/Isotype Monoclonal mouse lgG2a. Kappa
Application /
Description CD25 antibodies selectively target and deplete activated T cells, particularly those expressing CD25, making them potential therapeutic tools for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. They modulate the immune response by reducing the number of activated T cells, thereby alleviating symptoms.In organ transplantation, CD25 antibodies serve as immunosuppressants to prevent the recipient's rejection of the graft, reducing T cell activation and improving transplant success rates. In cancer treatment, CD25 antibodies aim to improve the immune suppression in the tumor microenvironment, restoring anti-tumor immune responses by targeting regulatory T cells. Overall, CD25 antibodies demonstrate broad application potential in the treatment of autoimmune diseases, management of organ transplantation, and cancer immunotherapy, helping to regulate and optimize immune responses.
Formulation phosphate-buffered solution, pH 7.2.
